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Abstract
Background: Phorbol myristate acetate (PMA) is a strong neutrophil activator and has been used to induce acute
lung injury (ALI). Niacinamide (NAC) is a compound of B complex. It exerts protective effects on the ALI caused by
various challenges. The purpose was to evaluate the protective effects of niacinamide (NAC) on the PMA-induced
ALI and associated changes.
Methods: The rat’s lungs were isolated in situ and perfused with constant flow. A total of 60 isolated lungs
were randomized into 6 groups to received Vehicle (DMSO 100 μg/g), PMA 4 μg/g (lung weight), cotreated
with NAC 0, 100, 200 and 400 mg/g (lung weight). There were 10 isolated lungs in each group. We measured
the lung weight and parameters related to ALI. The pulmonary arterial pressure and capillary filtration coefficient
(Kfc) were determined in isolated lungs. ATP (adenotriphosphate) and PARP [poly(adenosine diphophate-ribose)
polymerase] contents in lung tissues were detected. Real-time PCR was employed to display the expression of
inducible and endothelial NO synthases (iNOS and eNOS). The neutrophil-derived mediators in lung perfusate
were determined.
Results: PMA caused increases in lung weight parameters. This agent produced pulmonary hypertension and
increased microvascular permeabilit y .I tr e s u l t e di nd e c r e a s ei nA T Pa n di n c r e a s ei nP A R P .T h ee x p r e s s i o no f
iNOS and eNOS was upregulated following PMA. PMA increased the neutrophil-derived mediators. Pathological
examination revealed lung edema and hemorrhage with inflammatory cell infiltration. Immunohistochemical
stain disclosed the presence of iNOS-positive cells in macrophages and endothelial cells. These
pathophysiological and biochemical changes were diminished by NAC treatment. The NAC effects were dose-
dependent.
Conclusions: Our results suggest that neutrophil activation and release of neutrophil-derived mediators by PMA
cause ALI and associated changes. NO production through the iNOS-producing cells plays a detrimental role in the
PMA-induced lung injury. ATP is beneficial, while PARP plays a deteriorative effect on the PMA-induced ALI. NAC
exerts protective effects on the inflammatory cascade leading to pulmonary injury. This B complex compound may
be applied for clinical usage and therapeutic regimen.
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Niacinamide or nicotinamide is a compound of the solu-
ble B complex. It exerts inhibitory effects on the poly
(ADP-ribose) synthase (PARS) or poly (ADP-ribose)
polymerase (PARP). The nuclear enzyme can be acti-
vated by strand breaks in DNA caused by reactive oxy-
gen species and peroxynitrite [1-3]. PARP is cytotoxic
by massive depletion of intracellular nicotinamide ade-
nine dinucleotide (NAD
+) and adenosine triphosphate
(ATP). Inhibition of PARP activity reduces the ische-
mia-reperfusion injury of the heart, skeletal muscle, and
brain [3-5]. In addition, PARP inhibition with a specific
blocker, 3-aminobenzamide attenuates the acute lung
injury induced by endotoxin [6].
The inhibitory effects of niacinamide or its related
substances, nicotinamide and nicotinic acid, on the
PARP activity are protective to cell damage caused by
oxidative stress [7-10]. Our laboratory has reported that
PARS or PARP inhibition with niacinamide attenuates
the ischemia-reperfusion hepatic injury [11].
Phorbol myristate acetate (12-O-tetradecanoyl-phor-
bol-13-acetate, PMA), an ester derivative from croton
oil has been used to induce acute lung injury (ALI) in
animal experiments [12,13]. PMA is a strong neutrophil
activator. It leads to neutrophil activation and recruit-
ment. Consequently, release of neutrophil mediators
such as neutrophil elastase and other factors results in
severe acute lung injury [14-17].
The present study was designed to test the protective
effects of niacinamide on the PMA-induced ALI and
associated changes. The beneficial effects of niacinamide
were assessed in a dose-dependent fashion using various
doses. We also aimed to elucidate the mechanism of
action of this B-complex agent.
Methods
Animal preparation
We used male Spaque-Dawley (SD) rats, 12-14 wk-old,
weighing 360-380 g. The animals were obtained from
the National Animal Center and housed in the Univer-
sity Laboratory Animal Center with good environment
control. The animal experiment was approved by the
University Committee of Laboratory Animal Care and
Use, and followed the guidelines of the National Animal
Research Center. The room temperature was maintained
at 21 ± 1°C under a 12/12 hr light/dark regimen. Food
and water were provided ad libitum.
Isolation and perfusion of the lung in Situ
We followed the procedures for the preparation of iso-
lated and perfused rat’sl u n g sin situ [18,19]. Rats were
anesthetized with an intraperitioneal injection of pento-
barbital (40 mg/kg) and intubated with an endotracheal
tube. A rodent ventilator provided ventilation with a
mixture of 95% room air and 5% carbon dioxide. The
r e s p i r a t o r yr a t ea n dt i d a lv o l u m ew e r e6 0 - 6 5b r e a t h s /
min and 2-3 ml, respectively. The inspiratory and
expiratory pressures were 5 and 1 cm H2O. A vertical
incision was made along the midline of the thorax.
Heparin (1 U/g) was then injected into the right ventri-
cle. An afferent line (silicon tubing) was then inserted
into the pulmonary arterial trunks via the right ventricle,
while an efferent line (silicon tubing) was inserted into
the left atrium via the left ventricle. Blood (10-15 ml)
was collected for later use.
The pulmonary trunk and the aorta were then tied off.
T h ei s o l a t e dp e r f u s e dl u n g sw e r el e f tin situ,a n dt h e
whole rat was placed on an electronic balance. The digi-
tal signals of the electronic balance were converted to
analog signals by a digital-to-analog converter and were
recorded on a polygraph recorder. Weight changes were
precalibrated on the electronic balance before prepara-
tion for the experiment. In this isolated lung prepara-
tion, we have verified that the changes in body weight
(BW) reflect the lung weight (LW) changes [18,19].
The isolated lungs were perfused with heparinized
blood (10 ml) with Krebs-Heseleit balanced salt solution
(5 ml). The perfusion system included a venous reser-
voir and a roller pump. The perfusate was circulated via
the roller pump to maintain a constant flow. The
venous blood was diverted via the efferent line into the
reservoir. The later was placed in a 38°C water bath for
constant temperature.
Pulmonary arterial pressure (PAP) and venous pres-
sure (PVP) were measured from sideports connected to
the afferent and efferent tubings. The lungs were per-
fused with a constant flow (10-14 ml/min). Flow rate
was adjusted to maintain the initial PAP at 15-16
mmHg. The PVP was kept at 0-1 mmHg by adjusting
the height of efferent outflow tubing. The changes in
PAP at a constant-flow condition reflect the changes in
pulmonary vascular resistance.
Lung weight (LW), LW/body weight ratio (LW/BW) and LW
gain (LWG)
Lung weight (LW) was obtained from 20 euthanized rats
by an intravenous sodium pentobarbital (100 mg/kg).
The initial LW was estimated from an equation relating
to the body weight (BW) [18,19]. The LW was then
plotted against BW for a regression equation:
LW

g

= 0.0015 × BW

g

+ 0.034
LWG was obtained by the increase in LW and also
calculated as:
LWG = ﬁnal LW − initial LW
Lin et al. Journal of Biomedical Science 2012, 19:27
http://www.jbiomedsci.com/content/19/1/27
Page 2 of 13Microvascular permeability (Kfc)
Capillary filtration coefficient (Kfc) as an index of micro-
vascular permeability was calculated from the increase in
LW produced by an elevation in PVP. The Kfc was defined
as the initial weight gain rate (g/min) divided by PVP (10
cm H2O) and LW, expressed as g/min/cmH2O/100 g.
During the experiment, PVP was rapidly elevated by 10
cm H2O for 7 mins to measure Kfc. This hydrostatic chal-
lenge elicited a biphasic increase in LW: an initial rapid
component, followed by slow and steady component. The
slow component of the weight gain was plotted on a semi-
log scale as a function of time. The capillary filtration rate
was obtained by extrapolating the slow component of the
weight gain back to zero time [18,19].
Exhaled NO
An increase in exhaled NO concentration has been used
as an early marker of lung inflammation or injury
[20,21]. We measured the NO concentration in expired
air. A specimen of exhaled air (300 ml in 30 min) was
suctioned into a gas purge chamber preciously evacu-
ated to remove oxygen. The NO concentration was
rapidly determined after air collection. The measure-
ment of NO with a chemiluminescence analyzer (Sievers
270B NOA; Sievers Institute, Denver, CO, USA) was
based on the principle that NO interacts with ozone to
generate chemiluminescent light. The chemilumines-
cence is directly proportional to the NO level. In addi-
tion to a photomultiplier tube, an ozone generator and
ag a sc h a m b e rw e r ei n c l u d e d .T h eo z o n eg e n e r a t o rw a s
used to produce ozone internally. The exhaled NO was
measured every 30 min after introduction of PMA into
the lung perfusate. It reached its peak depending on the
experimental conditions. The peak value was taken as
the NO concentration.
Protein concentration in bronchoalveolar lavage (PCBAL)
and Evans blue leakage
After the experiment, lungs were lavaged twice with sal-
ine (2.5 ml per lavage). Lavage samples were centrifuged
at 1,500 g at room temperature for 10 min. The PCBAL
was determined with a spectrophotometer by measuring
t h ec h a n g ei na b s o r b a n c ea t6 3 0n ma f t e rt h ea d d i t i o n
of bromocresol green [18,22]. Five mins before the end
of the experiment, Evans blue dye (1 mg) was given into
the lung perfusate. The Evans blue content in lung tis-
sue was determined spectrophotometrically at an optical
density 620 nm [22].
Nitrate/nitrite, methyl guanidine, tumor necrosis factora
and interleuin-1b
Samples (0.5 ml) were taken from the lung perfusate 1
hr before and at various time points after PMA adminis-
tration. The samples were centrifuged at 3,000 g for 10
mins. The supernatant was used for determination of
nitrate/nitrite with high-performance chromatography
[23,24]. The formation of methyl guanidine (MG) has
been identified as an index of hydroxyl radical produc-
tion [25]. It was determined with its fluorescence spec-
trum (Jasco 821-FP, Spectroscopic Co., Tokyo, Japan).
T h ee m i s s i o nm a x i m u mw a ss e ta t5 0 0n ma n dt h e
excitation maximum at 398 nm. The assay was cali-
brated with authentic MG (Sigma M0377). Tumor
necrosis factora (TNFa)a n di n t e r l e u k i n - 1 b (IL-1b)w e r e
measured with antibody enzyme-linked immunosorbent
assays (ELISAs) with a commercial antibody pair,
recombinant standards, and a biotin-streptavdin-peroxi-
dase detection system (Endogen, Rockford, IL, USA). All
agents, samples, and working standards were prepared
at room temperature according to the manufacturer’s
directions. The optical density was measured at 450/540
nm wavelengths by automated ELISA readers.
Neutrophil elastase, myeloperoxidase, and
malondialdehyde activity
The neutrophil elastase (NE) was determined with a
synthetic substrate, N-methoxysuccinyl-Ala-Ala-Pro-Val-
p-nitroanilide as described previously [15,18]. In brief,
samples were incubated in 0.1 M Tris-HCl buffer (pH
8.0) containing 0.5 M Nacl and 1 mM substrate at 37°C
for 24 hrs. After incubation, p-nitroanilide release was
measured spectrophotometrically at 450 nM and consid-
ered NE activity.
To measure the myeloperoxidase (MPO) activity in
lung perfusate, the samples were mixed with 2 ml of
potassium phosphate buffer (50 mM, pH 6.0) containing
0.5% cetyltrimethylammonium bromide and were centri-
fuged at 2,500 g for 10 mins at 4°C. The supernatant
was diluted with dilution buffer, then mixed with an
assay buffer composed of 0.00107% H2O2 in potassium
phosphate buffer and o-dianisidine. The reaction mix-
ture was incubated at room temperature. The change in
absorbance at 450 nm over 1 min was detected spectro-
photometrically. The MPO activity was expressed as
units per ml of lung perfusate using the absorbance of
MPO standard (Elastine Products, Detroit, MC., USA).
The procedures were basically followed those by
Kinoshita et al. [26].
Malondialdehyde (MDA) was measured by thiobarbi-
turic and reaction. The principle of the method depends
on the development of pink color produced by the
interaction of barbituric acid with MDA as a result of
lipid peroxidation. Tetraetoxypropane was used as stan-
dard [27,28].
ATP content
Lungs were harvested after the experiments. A BioOrbit
ATP Assay kit (Bio-Orbit Oy, Turku, Finland) was used
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cence technique. The assay was based on quantitative
measurement of a stable level of light as a result of an
enzyme reaction catalysed by luciferase. Under the effect
of luciferase, the luminescence evoked by ATP and luci-
ferin interaction was recorded photometrically after
amplification by a photomultiplier. The sensitivity of
ATP was in a nanomolar range. The luciferin-luciferase
reagent was used according to the manufacturer’sm a n -
ual. ATP served as the standard. The test procedures
have been described previously [11,29].
PARP activity
PARP activity in the harvested lung tissue was measured
with a commercially available assay kit (Genzyme Diag-
nostics, Cambridge, MA, USA). Lung tissue samples
were placed on ice in 2 mL buffer containing 50 mM
Tris Cl (pH 8.0), 25 mM MgCl2 and 0.1 mM phenyl-
methylsulfonyl fluoride. The samples were homogenized
for 30 s and then sonicated for 20 s using an ultrasonic
homogenizer. The suspension was centrifuged at 3,000
× g for 5 min at 4°C. Supernatant containing 20 μg pro-
tein, PARS buffer, 1 mM NAD, 2 μCi
32P-labelled NAD
(1 μCi/μL) and distilled water was mixed in a microcen-
trifuge tube. The reaction was allowed to continue at
room temperature for 1 min and was stopped by adding
900 μL of tricarboxylic acid. Enzyme activity was deter-
mined by measuring the incorporation of radiolabelled
NAD as PARP catalysed the poly (ADP) ribosylation of
proteins. The labeled ADP was determined by scintilla-
tion counting after tricarboxylic acid precipitation onto
a filter. The procedures and calculation of PRRP activity
were carried out according to those described by Pulido
et al. [30].
Detection of iNOS and eNOS mRNA in lung tissue
Real-time polymerase chain reaction (RT-PCR) was
employed for the detection of iNOS and eNOS mRNA
expression. PCR primers and TaqMan-MGB probes
were designed using Primer Express V.2.0 software
(Applied Biosystems Inc., Foster, CA, USA) based on
the sequences from GenBank. TaqMan-MGB probes
were labeled with 6-carboxy-fluorescein (FAM) as the
reporter dye. Real-time PCR was performed in a two-
step process: In the first step, sample RNA (100 ng) was
reverse-transcribed with 50 ng random hexamers in a
volume of 20 μl using 200 U of Superscript III reverse
transcriptase and 40 U of RNaseOUT recombinant
RNase inhibitor (both from Invitrogen, Carlsbad, CA,
USA). In the second, real-time PCR was carried out in a
MicroAmp Optical 96-well plate using TaqMan Master
Mix (Applied Biosystems Inc.), with 5 μl cDNA in each
well. PCR reactions were monitored in real time using
the ABI PRISM 7000 Sequence Detector (Applied
Biosystems Inc. Foster, CA, USA). The thermal cycling
conditions for real-time PCR were a) 50°C for 2 mins,
b) 95°C for 10 mins, c) 40 cycles of melting (95°C, 15
sec) and d) annealing/extension (60°C, 60 sec).
Immunofluorescent stain
Immunofluorescent staining was used to detect the activ-
ities of nitrotyrosine and iNOS in lung tissue using speci-
fic polyclonal antibodies as described previously [31,32].
Lung pathology and immunohistochemical examinations
Lung tissue was fixed in 10% formaldehyde for 24 hrs
and then rinsed with tap water to remove formaldehyde.
For light microscopic examination, lung tissue was
dehydrated with graded alcohol and then embedded in
paraffin at 60°C. A series of microsections (5 μm) was
stained with hematoxylin and eoxin. For quantification
of lung injury score, we employed a modified grading
method reported previously [21,28]. Various degree of
lung injury score (LIS) were assessed as follows: degree
0, 1, 2 and 3 for no, mild, moderate and severe edema,
respectively. For inflammatory cell infiltration, the scor-
ing was similar to the edema extent: 0-3 for no, mild,
moderate and severe cell infiltration. The histopatholo-
gical assessment was performed in a blind fashion by
several laboratory assistants. The individual scores were
added together to obtain a final score, ranging from 0-6.
Antigen retrieval immunohistochemical stain was used
to identify the source of inducible NO synthase (iNOS)
in lung cells [33,34].
Administration of PMA and niacinamide (NAC)
PMA (4 μg/g) and NAC at various doses were added
into the lung perfusate via the venous reservoir [35,36].
NAC was given simultaneously with PMA [20,37,38].
Examinations of biochemical factors were taken before
administration of PMA and NAC, and at the end of the
experiments.
Experimental protocol
A total of 60 isolated lungs were randomized into 6
groups to receive Vehicle (DMSO 100 μg/g), and PMA
4 μg/g (lung weight) cotreatment with NAC 0, 100, 200
and 400 mg/g (lung weight). There were 10 isolated
lungs in each group. The doses of PMA and NAC were
used in accordance with previous studies [12,13,20]. The
experiments were observed for 120 mins.
Statistical analysis
All data were expressed as mean ± SEM. Comparisons
within and among groups were made using one-way ana-
lysis of variance with repeated measures, followed a post
hoc comparison with Newman-Keuls test. Differences
were considered to be statistically significant at p < 0.05.
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Lung weight/body weight (LW/BW) ratio, LW gain (LWG),
exhaled NO and protein concentration in bronchoalveolar
lavage (PCBAL)
Figure 1 illustrates the PMA effects on the LW/BW
ratio, LWG, exhaled NO and PCBAL. Cotreatment with
NAC mitigated the PMA-induced changes. The protec-
tive effects of NAC were dose-dependent.
Pulmonary arterial pressure (PAP) and capillary filtration
coefficient (Kfc)
In isolated lungs, PMA caused increases in PAP and Kfc.
The PMA-induced pulmonary hypertension and
increased microvascular permeability were attenuated by
NAC. The protection was dependent on the NAC doses
(Figure 2).
Nitrate/nitrite, methyl guanidine, tumor necrosis factora
and interleukin-1b
PMA caused increases in these biochemical factors.
Cotreatment with NAC reversed the PMA-induced
changes. The effects of NAC were dose-dependent (Fig-
ure 3).
ATP and PARP activities in lung tissues
Figure 4 displays the effects of PMA and NAC on the
ATP and PARP contents in lung tissues. PMA caused
decrease in ATP and increase in PARP in lung tissues.
Cotreatment with NAC mitigated the PMA-induced
changes. The protection was dose-dependent.
Expression of iNOS and eNOS mRNA
The expression of iNOS and eNOS in lung tissues was
shown on Figure 5. PMA upregulated the iNOS and
eNOS. The expression of iNOS was more obvious than
eNOS. Coadministration with NAC attenuated the
iNOS and eNOS expression. The effects were dose-
dependent (Table 1).
NE, MPO and MDA
In lung perfusate, PMA caused increases in NE, MPO
and MDA. NAC at different doses reduced the PMA-
induced changes in these mediators. The effects of
reduction depended on the doses (Table 2).
Nitrotyrosine and iNOS immunofluorescence
PMA elicited significant increases in nitrotyrosine and
iNOS immunofluorescent activities. The enhancement
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Figure 1 The lung weight (LW) to body weight (BW) ratio (A), LW gain (LWG, B), exhaled nitric oxide (NO, C), and protein
concentration in bronchoalveolar lavage (PCBAL, D). Phorbol myristate acetate (PMA) significantly increased these lung variables.
Administration of niacinamide (NAC) attenuated the PMA-induced changes in a dose-dependent manner. PMA at a dose of 4 μg/g (PMA 4)
(lung weight) was given into the lung perfusate. PMA 0 denotes the control lungs without receiving PMA. NAC 0, 100, 200, and 400 indicate the
doses of NAC at mg/g (lung weight). *p < 0.05 PMA 4 vs. PMA 0.
§p < 0.05 vs. NAC 0 (dose effects of NAC).
+p < 0.05 vs. the values of PMA 4.
There were 10 isolated lung preparations in each group.
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PMA was attenuated by co-treatment with NAC. The
effects of NAC were dose dependent (Figure 6).
Pulmonary pathology and immunohistochemical
examinations
Figure 7 shows the histopathological micrographies of the
lungs following PMA at 4 μg/g. The pulmonary pathologi-
cal changes included edema and hemorrhage with infiltra-
tion of inflammatory cells. The pulmonary pathology was
diminished or prevented by coadministration of NAC. The
protective effects of NAC were operated in a dose-depen-
dent fashion. PMA dose-dependently increased the LIS,
NAC reduced the LIS caused by PMA. The reductions
were also dose-dependent (Table 3).
Immunohistochemical stain with antigen retrieval
technique revealed the presence of iNOS-positive cells
in alveolar macrophages and endothelial cells. The num-
ber of iNOS-producing cells seemed to be more abun-
dant in macrophages than endothelial cells (Figure 8). It
appeared that the number of iNOS-staining macro-
phages and endothelial cells was decreased by treatment
with NAC (data not shown).
Discussion
Previous studies have reported that niacinamide exerts
protective effects on the acute lung injury induced by
various challenges including endotoxin, ischemia/reper-
fusion, and oxidative stress [7,9,20,35-38]. In the present
investigation, we found thatt h i sc y t o p r o t e c t i v ea g e n t
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Figure 2 Pulmonary arterial pressure (PAP) and capillary filtration coefficient (Kfc) in isolated lungs. The denotations and statistical
symbols are the same as Figure 1.
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myristate acetate in isolated lungs. Niacinamide dimin-
ished the pulmonary hypertension and increase in
microvascular permeability following PMA introduction
into isolated lungs. This B complex compound
decreased ATP, while increased PARP. PMA also
induced the upregulation of iNOS and eNOS. NAC
mitigated the upregulation. Neutrophil activation by
PMA led to releases of neutrophil elastase, myeloperoxi-
dase and malondialdehyde in plasma and lung perfusate.
NAC abrogated the biochemical changes caused by
PMA. The PMA-induced ALI was associated with severe
pulmonary edema and hemorrhage with inflammatory
cell infiltration. Coadministration with NAC attenuated
the lung pathology. NAC reduced the lung injury score
after PMA. The results indicate that PMA exerts a detri-
mental role. The beneficial effects of NAC are dose-
dependent.
Immunofluorescent staining revealed that PMA pro-
duced marked increases in nitrotyrosine and iNOS acti-
vies. The PMA effects on the nitrotyrosine and iNOS in
lung tissues were mitigated by NAC in a dose-depen-
dent fashion. NO is a free radical. The formation of
nitrotyrosine and peroxynitrate by NO conjugation with
reactive oxygen radicals such as peroxide and superox-
ide is extremely toxic to the lung in sepsis, ischemia-
reperfusion, infections and phorbol myristate acetate as
well [21,31,32,35-41].
I nt h el u n g s ,P A R Pp l a y sak e yr o l ei nt h em i c r o v a s c u -
lar platelet-endothelial cell interaction induced by endo-
toxin, acute lung inflammation following intratracheal
administration of endotoxin, induction of asthma, an leu-
kocyte recruitment in systemic endotoxemia [6,42,43].
These cellular interactions, tissue inflammatory changes
and subsequent alterations in adhesion molecules are
likely to be the fundamental basis for the pathogenesis of
lung injury. The present study revealed that PMA
increased the PARP activity, while reduced the ATP con-
tent. NAC attenuated the PMA-induced increase in
PARP activity and restored the ATP content. In the
regard, NAC exerts not only cytoprotective actions, but
also anti-inflammatory effects with restoration of ATP.
Pharmacological inhibition and gene knockout
mutants of PARS or PARP have become a new
approach for the experimental therapy of various disor-
ders, such as endotoxin shock, stroke, I/R injury, lung
inflammation and others [42-44]. Activation of PARS or
PARP produces cytotoxicity and subsequent cell death
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Figure 3 Concentration of nitrate/nitrite (A) methyl guanidine (B), tumor necrosis factora (C), and interleukin-1b (D) in lung perfusate.
Note the dose-dependent elevation in these factors by PMA, and the depression by coadministration with NAC. Abbreviations and statistical
symbols are the same as Figure 1.
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Figure 5 The expression of inducible and endothelial nitric oxide synthase mRNA (iNOS and eNOS) using real-time RT-PCR.G A P D H
serves as internal contrast. PMA upregulated iNOS significantly and eNOS modestly. NAC treatment reduced the iNOS and eNOS expression. To
avoid redundance, only the effects of NAC 100 and 400 mg/g on PMA 4 μg/g are shown. PMA 0 serves as control.
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Page 8 of 13Table 1 The expression of inducible and endothelial
nitric oxide synthase (iNOS and eNOS) in lung tissue
iNOS/GAPDH eNOS/GAPDH
PMA 0 0.23 ± 0.02 0.44 ± 0.04
PMA 4 3.42 ± 0.12* 2.84 ± 0.14*
NAC 0 3.51 ± 0.14 3.02 ± 0.11
NAC 100 0.34 ± 0.04
§+ 2.01 ± 0.09
§+
NAC 200 0.19 ± 0.06
§+ 1.46 ± 0.07
§+
NAC 400 0.21 ± 0.04
§+ 0.62 ± 0.08
§+
Values are means ± SEM (n = 10). The data include 10 isolated lung
preparations. *p < 0.05 PMA 4 vs. PMA 0.
§p < 0.05 vs. NAC 0 (dose effects of
NAC).
+p < 0.05 vs. the values of PMA 4. PMA, phorbol myristate acetate; and
NAC, niacinamide. The symbols 0 and 4 denote the dose of PMA at μg/g
(lung weight), and 0, 100, 200 and 400 of NAC at mg/g (lung weight). The
expression of glyceraldehyde phosphate dehydrogenase (GAPDH) was used as
an internal standard.
Table 2 Neutrophil elastase (NE), myeloperoxidase (MPO),
and malondialdehyde (MDA)
NE
(nmol/ml)
MPO
(unit/ml)
MDA
(nmol/ml)
PMA 0 0.22 ± 0.03 4.23 ± 0.08 33.51 ± 2.56
PMA 4 21.42 ± .018* 49.44 ± 0.31* 486.51 ± 12.42*
NAC 0 22.14 ± 0.16 51.62 ± 0.33 512.46 ± 14.36
NAC 100 10.21 ± 0.14
§+ 24.36 ± 0.26
§+ 246.82 ± 4.92
§+
NAC 200 4.22 ± 0.08
§+ 12.12 ± 0.12
§+ 112.34 ± 4.86
§+
NAC 400 0.36 ± 0.04
§+ 5.63 ± 0.09
§+ 46.74 ± 0.24
§+
Values are means ± SEM (n = 10). The data collections, abbreviations and
statistical symbols are the same as Table 1.
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Figure 6 Immunofluorescence of nitrotyrosine and iNOS in lung tissue. Note the significant elevation of nitrotyrosine and iNOS after PMA.
Coadministration of NAC reduces the PMA-induced increases in nitrotyrosine and iNOS in a dose-dependent manner. The abbreviations and
statistical symbols are the same as Figure 1.
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Page 9 of 13and organ dysfunction. The results of the present study
demonstrated that treatment with NAC abrogated ALI
induced by PMA in lungs.
In addition to the role of PARP in ALI due to various
causes, iNOS may also be a crucial factor in lung
damage. In endotoxin-induced lung damage, many stu-
dies have provided evidence to suggest that NO produc-
tion through iNOS is harmful to the lungs in various
species and different causes [41-46]. In patients with
lung inflammation or injury, the iNOS expression and
PMA 0 
NAC 400 + PMA 4 
PMA 4 
NAC 100 + PMA 4 
Figure 7 Lung pathology in various groups. PMA caused pulmonary edema and hemorrhage with inflammatory cell infiltration. NAC
abrogated the pulmonary pathology in a dose-dependent fashion. To minimize redundance, only the effects of PMA 0 and 4 μg/g and NAC
100 and 400 mg/g on the PMA (4 μg/g) induced lung pathology are shown.
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Page 10 of 13nitrotyrosine activity were increased [31,32]. The iNOS
upregulation was found in subjects suffering from lep-
tospirosis and scrub typhus [34,47]. PARP was involved
in nuclear factor (NF)-B expression and thereby acti-
vated NOS. ADP ribosylaion is required to activate NF-
B-mediated iNOS gene transcription [48,49]. Remick et
al. [50] also suggested that ADP ribosylation was crucial
in the signaling pathway which leads to NOS mRNA
expression. PARP inhibitors prevent NOS induction,
iNOS mRNA expression and TNFa release in inter-
feron- and lipopolysaccharide-stimulated macrophages.
After inhibition of PARP, iNOS expression, iNOS activ-
ity and NO production were reduced [6]. PARP inhibi-
tion also reduced the production of peroxynitrite, and
prevented the presence of nitrotyrosine in the tissue
[51]. It is likely that iNOS is involved in the pathogen-
esis of tissue injury following endotoxemia, ischemia-
reperfusion and other challenges in various organs. In
the present study, Real-time PCR and immunofluores-
cent staining revealed that PMA upregulated iNOS
expression. The upregulation was attenuated by cotreat-
ment with NAC.
Immunohistochemical stain observed the major sites
of iNOS-producing cells were the alveolar macrophage
and endothelial cells. The present study strongly sug-
gests that NO production through the iNOS isoform
plays a deleterious role in the PMA-induced lung injury.
NAC possesses protective effects on the inflammatory
responses to PMA. In this regard, the B-complex agent
may act as a NOS inhibitor. Furthermore, ATP reduc-
tion and PARP increase caused by PMA could be the
pathogenic mechanism of this neutrophil activator.
We are probably the first to demonstrate that the
iNOS-positive cells following neutrophil activation by
PMA reside mainly in the alveolar macrophages and
endothelial cells. A recent study from our laboratory
using electron microscopy has revealed the PMA caused
endothelial damage [21]. The sites of cells that produce
NO are similar to those observed in patients with lung
infections [34,47]. We may propose that NO production
through the iNOS-producing cells accounts for the lung
injury and subsequent changes. In animals with sepsis,
the NO production through the iNOS isoform was gen-
erated from the lung [20,21,52]. The present investiga-
tion further identified the sources of iNOS-positive cells.
Neutrophil activation and recruitment are an impor-
tant step in the pathogenesis of ALI or acute respiratory
syndrome (ARDS). We have provided evidence to show
that PMA increases the neutrophil elastase, myeloperox-
idase and malondialdehyde inl u n gp e r f u s a t e .N A Cs i g -
nificantly attenuated the increases in neutrophil derived
mediators. The effects of NAC were operated in a dose-
dependent fashion. Clinical investigations and trials are
needed for the therapeutic application of this compound
of B complex.
Conclusion
In conclusion, neutrophil activation by PMA causes ALI
and associated changes. NO release through the iNOS-
positive cells is detrimental to the lung. The major sites
of NO production are in the alveolar macrophages and
endothelial cells. Inhibition of iNOS and/or PARP with
N A Ci sl i k e l yt h ek e ym e c h a n i s mo ft h ep r o t e c t i v e
Table 3 The lung injury score (LIS)
LIS
PMA 0 0.12 ± 0.04
PMA 4 5.82 ± 0.22*
NAC 0 5.74 ± 0.24
NAC 100 2.38 ± 0.14
§+
NAC 200 1.46 ± 0.12
§+
NAC 400 0.24 ± 0.06
§+
Values are means ± SEM (n = 10). The data collections, abbreviations and
statistical symbols are the same as Table 1.
A 
B 
Figure 8 Expression of inducible nitric oxide synthase (iNOS) in
endothelial cells (A) and alveolar macrophages (B, arrows).
Antigen retrieval immunohistochemical stain of lung tissue sections
was used (original magnification ×200).
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Page 11 of 13effects of NAC on the PMA-induced lung injurious
abnormalities.
This study investigated the effects and mechanisms of
action of niacinamide (B complex) on the acute lung
injury produced by a neutrophil activator, phorbol myr-
istate acetate. The findings may have therapeutic values
in clinical conditions of acute respiratory distress
syndrome.
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